Abstract
Background PRKN biallelic pathogenic variants are the most common cause of autosomal recessive early-onset Parkinson’s disease (PD). However, the variants responsible for suspected PRKN-PD individuals are not always identified with standard genetic testing.
Objectives Identify the genetic cause in two siblings with a PRKN-PD phenotype using long-read sequencing (LRS).
Methods The genetic investigation involved standard testing using successively multiple ligation probe amplification (MLPA), Sanger sequencing, targeted sequencing, whole-exome sequencing and LRS.
Results MLPA and targeted sequencing identified one copy of exon four in PRKN but no other variants were identified. Subsequently, LRS unveiled a large deletion encompassing exon 3 to 4 on one allele and a duplication of exon 3 on the second allele; explaining the siblings’ phenotype. MLPA could not identify the balanced rearrangement of exon 3.
Conclusions This study highlights the potential utility of long-read sequencing in the context of unsolved typical PRKN-PD individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the Intramural Research Programs of the National Institute on Aging (NIA). This work was also supported by the Fondation pour la Recherche Medicale (FRM, MND202004011718), the Fondation de France, la Federation pour la Recherche sur le Cerveau (FRC), France-Parkinson Association, and the French program "Investissements d'avenir" (ANR-10-IAIHU-06).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Local ethics committee (Number 44,814; INSERM, CCPPRB of Groupe Hospitalier Pitie-Salpetriere, Paris, France) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Relevant conflicts of interest/financial disclosures : The authors declare that they have no conflict of interest.
Funding sources: This work was supported in part by the Intramural Research Programs of the National Institute on Aging (NIA). This work was also supported by the Fondation pour la Recherche Médicale (FRM, MND202004011718), the Fondation de France, la Fédération pour la Recherche sur le Cerveau (FRC), France-Parkinson Association, and the French program “Investissements d’avenir” (ANR-10-IAIHU-06).
Data Availability
Data used in the preparation of this article are available upon request to the authors.
